Analysts Set Expectations for CRDF Q1 Earnings

Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Analysts at William Blair issued their Q1 2026 earnings per share estimates for Cardiff Oncology in a research note issued to investors on Thursday, February 27th. William Blair analyst A. Hsieh forecasts that the company will post earnings per share of ($0.26) for the quarter. The consensus estimate for Cardiff Oncology's current full-year earnings is ($0.99) per share. William Blair also issued estimates for Cardiff Oncology's Q2 2026 earnings at ($0.26) EPS, Q3 2026 earnings at ($0.28) EPS and Q4 2026 earnings at ($0.28) EPS.

A number of other research analysts have also issued reports on CRDF. HC Wainwright upped their price target on shares of Cardiff Oncology from $13.00 to $17.00 and gave the company a "buy" rating in a research note on Friday. Piper Sandler upped their target price on Cardiff Oncology from $7.00 to $10.00 and gave the company an "overweight" rating in a research report on Friday, December 13th.

Cardiff Oncology Stock Down 1.2 %

Shares of CRDF traded down $0.05 during mid-day trading on Monday, hitting $3.78. 494,764 shares of the company traded hands, compared to its average volume of 1,175,174. The company has a market capitalization of $193.03 million, a PE ratio of -4.02 and a beta of 1.77. The business has a 50 day moving average of $4.06 and a 200 day moving average of $3.25. Cardiff Oncology has a 1-year low of $2.01 and a 1-year high of $6.42.

Insider Buying and Selling

In other Cardiff Oncology news, Director Gary W. Pace acquired 350,115 shares of the company's stock in a transaction dated Wednesday, December 11th. The shares were acquired at an average cost of $2.60 per share, with a total value of $910,299.00. Following the acquisition, the director now directly owns 1,047,876 shares of the company's stock, valued at approximately $2,724,477.60. The trade was a 50.18 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 7.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Cardiff Oncology

Several hedge funds have recently added to or reduced their stakes in CRDF. Orbimed Advisors LLC acquired a new position in shares of Cardiff Oncology in the 4th quarter valued at about $6,677,000. Acorn Capital Advisors LLC purchased a new position in Cardiff Oncology during the fourth quarter valued at approximately $6,260,000. Adage Capital Partners GP L.L.C. acquired a new position in Cardiff Oncology in the fourth quarter valued at approximately $5,609,000. Geode Capital Management LLC boosted its position in Cardiff Oncology by 5.9% in the 4th quarter. Geode Capital Management LLC now owns 982,878 shares of the company's stock worth $4,266,000 after purchasing an additional 54,646 shares in the last quarter. Finally, State Street Corp grew its stake in shares of Cardiff Oncology by 3.4% during the 3rd quarter. State Street Corp now owns 832,652 shares of the company's stock worth $2,223,000 after purchasing an additional 27,628 shares during the period. 16.29% of the stock is owned by hedge funds and other institutional investors.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.